$BCDA SEC Filings

Bought 200 shares ($190) · Bought 300 shares ($285)

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for HelixTM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter

SUNNYVALE, Calif. – October 7, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the upcoming presentation of a sc...

SUNNYVALE, Calif. – October 1, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-S...

Bought 1,000 shares ($1.03K)

Bought 1,900 shares ($2K)

SUNNYVALE, Calif. – September 23, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones.

As previously disclosed, on August 19, 2026, BioCardia, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The NASDAQ Stock Market, LLC (“Nasdaq”) indicating that, for the last 30 consecuti...

SUNNYVALE, Calif. – September 10, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., Pres...

Bought 800 shares ($872)

Bought 5,400 shares ($5.02K)

Bought 1,900 shares ($1.75K)

Bought 5,000 shares ($3.9K)

Bought 500 shares ($415)

Bought 2,800 shares ($2.46K) · Bought 1,500 shares ($1.29K)

Bought 5,500 shares ($5.34K) · Bought 1,000 shares ($900) · Bought 1,000 shares ($940)